secwatch.observer — SEC 8-K summary
======================================

Issuer:     Silence Therapeutics plc (SLN)
CIK:        0001479615
Form:       8-K
Filed at:   2026-08-10T11:20:14+00:00
Accession:  0001193125-26-341240
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Silence Therapeutics Q2 2026 net loss narrows to $12.3M; divesiran Phase 2 dosing complete
--------------------------------------------------------------------------------

- Net loss $12.3M ($0.09/share) vs $27.4M ($0.19/share) in Q2 2025; cash $72.1M at June 30, 2026.
- R&D expenses fell to $9.1M from $17.6M YoY, mainly due to zerlasiran Phase 3 readiness completion and lower personnel costs.
- Divesiran Phase 2 SANRECO trial completed patient dosing in 48 phlebotomy-dependent PV patients; EHA 2026 data presented.
- SLN312 (AZD1705) Phase 1 results from AstraZeneca collaboration presented at EAS 2026; favorable safety and dose-dependent lipid reductions.
- Preclinical SLN365 (GPR146) and SLN098 (INHBE) programs on track for potential IND filings in 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1479615/000119312526341240/0001193125-26-341240-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1479615/000119312526341240/d162225d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-341240

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer